Sarepta Therapeutics (NASDAQ:SRPT) Hits New 52-Week Low - Time to Sell?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report)'s share price reached a new 52-week low on Wednesday . The company traded as low as $99.50 and last traded at $102.86, with a volume of 1197230 shares. The stock had previously closed at $101.22.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on SRPT shares. HC Wainwright reaffirmed a "sell" rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, February 27th. Guggenheim upped their price target on Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. Piper Sandler cut their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 27th. Royal Bank of Canada cut their target price on Sarepta Therapeutics from $165.00 to $161.00 and set an "outperform" rating on the stock in a research report on Thursday, February 27th. Finally, Cantor Fitzgerald raised Sarepta Therapeutics from a "neutral" rating to an "overweight" rating and upped their target price for the company from $152.00 to $167.00 in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Sarepta Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $173.52.

Sarepta Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The company has a market cap of $9.83 billion, a PE ratio of 82.29 and a beta of 0.75. The company's 50-day simple moving average is $115.12 and its 200 day simple moving average is $122.01.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the sale, the director now directly owns 5,880 shares of the company's stock, valued at approximately $738,234. The trade was a 21.77 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the sale, the director now directly owns 22,840 shares of the company's stock, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of SRPT. CIBC Asset Management Inc lifted its holdings in shares of Sarepta Therapeutics by 3.3% in the third quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company's stock valued at $339,000 after purchasing an additional 86 shares in the last quarter. Louisiana State Employees Retirement System lifted its holdings in shares of Sarepta Therapeutics by 0.4% in the fourth quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company's stock valued at $3,222,000 after purchasing an additional 100 shares in the last quarter. EP Wealth Advisors LLC lifted its stake in shares of Sarepta Therapeutics by 2.2% during the fourth quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company's stock valued at $606,000 after buying an additional 105 shares during the period. Manchester Capital Management LLC lifted its stake in shares of Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after buying an additional 110 shares during the period. Finally, UMB Bank n.a. lifted its stake in shares of Sarepta Therapeutics by 36.0% during the fourth quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company's stock valued at $63,000 after buying an additional 138 shares during the period. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.